Financial Performance - The company's operating revenue for Q1 2025 was ¥336,233,032.74, a decrease of 9.83% compared to ¥372,901,239.16 in the same period last year[3] - Net profit attributable to shareholders was ¥41,213,565.38, down 31.37% from ¥60,053,057.57 year-on-year[3] - Basic and diluted earnings per share decreased by 31.25% to ¥0.44 from ¥0.64 in the previous year[3] - Operating profit for Q1 2025 was RMB 46,550,819.64, down 30.8% from RMB 67,419,323.41 in Q1 2024[16] - Net profit for Q1 2025 was RMB 37,246,620.09, representing a decline of 29.2% from RMB 52,633,265.21 in Q1 2024[17] - Other income for Q1 2025 was RMB 4,986,227.80, significantly lower than RMB 21,552,389.41 in Q1 2024[16] - The company reported an investment income of RMB 535,543.58 in Q1 2025, compared to a loss of RMB 2,848,852.32 in Q1 2024[16] Cash Flow - The net cash flow from operating activities was ¥41,518,009.56, reflecting a decline of 28.96% compared to ¥58,444,077.74 in the prior year[3] - Cash flow from operating activities for Q1 2025 was RMB 41,518,009.56, a decrease of 29.0% compared to RMB 58,444,077.74 in Q1 2024[20] - Cash flow from investing activities for Q1 2025 was negative RMB 124,534,450.17, compared to negative RMB 6,218,686.70 in Q1 2024[21] - Cash and cash equivalents at the end of Q1 2025 were RMB 122,212,903.47, down from RMB 459,206,280.89 at the end of Q1 2024[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,470,852,020.09, an increase of 0.46% from ¥2,459,641,144.78 at the end of the previous year[4] - The company's total liabilities decreased to CNY 596.1125 million as of March 31, 2025, from CNY 637.0621 million at the end of 2024[13] - As of March 31, 2025, total current assets amounted to CNY 1,389.6859 million, a decrease from CNY 1,433.2729 million as of December 31, 2024[11] - The total assets of the company as of March 31, 2025, were CNY 2,470.8520 million, compared to CNY 2,459.6411 million at the end of 2024[12] Shareholder Information - Shareholders' equity attributable to shareholders increased by 2.74% to ¥1,852,853,845.08 from ¥1,803,406,935.99 at the end of last year[4] - The total number of ordinary shareholders at the end of the reporting period was 5,130[8] - The equity attributable to shareholders of the parent company increased to CNY 1,852.8538 million as of March 31, 2025, from CNY 1,803.4069 million at the end of 2024[13] Research and Development - R&D investment totaled ¥26,602,707.31, a decrease of 15.36% from ¥31,428,966.58 in the same period last year, representing 7.91% of operating revenue[3] Revenue Breakdown - In Q1 2025, the revenue from formulation products was CNY 256.9953 million, while revenue from raw materials and intermediates was CNY 76.4986 million, and technical service revenue was CNY 2.2652 million[10]
华纳药厂(688799) - 2025 Q1 - 季度财报